AstraZeneca ((AZN)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Study Overview: AstraZeneca recently completed a study titled ‘Cross-sectional Study to Evaluate the Chronic Kidney Disease Prevalence Using a Creatinine Point-of-care Tool in Brazilian Adult Patients With Known CKD Risk Factors Randomly Selected.’ The study aimed to assess the prevalence of chronic kidney disease (CKD) in Brazil by screening adults with known risk factors using a point-of-care creatinine test. This research is significant as it seeks to address gaps in CKD knowledge and improve early detection and management in the Brazilian population.
Intervention/Treatment: The study utilized a point-of-care creatinine test to evaluate kidney function in participants. This test is designed to quickly identify abnormal kidney function, allowing for timely referral and further evaluation by nephrology specialists if necessary.
Study Design: The study was observational with a cohort model and a retrospective time perspective. It involved screening patients at local healthcare facilities and referring those with abnormal results for further laboratory confirmation and evaluation by nephrology teams.
Study Timeline: The study began on July 29, 2025, and was completed with the last update submitted on October 7, 2025. These dates are crucial as they mark the progression and completion of the study, providing a timeline for data collection and analysis.
Market Implications: This study update could positively influence AstraZeneca’s stock performance by highlighting the company’s commitment to addressing global health issues such as CKD. The findings may enhance investor sentiment by showcasing AstraZeneca’s role in pioneering healthcare solutions. In the broader industry context, this study underscores the importance of early detection tools in managing chronic diseases, potentially impacting competitors focused on similar health challenges.
The study is now completed, and further details are available on the ClinicalTrials portal.